Bermúdez AAD

Language: Spanish
References: 17
Page: 79-84
PDF size: 71.14 Kb.

ABSTRACT

Hepatitis C virus (HCV), is the major causative agent of non-A non-B hepatitis worldwide. There are 170 million chronic carriers at risk of developing liver cirrhosis and cancer. NS3 protease is essential for virus replication and is one of the most promising targets for specific anti- HCV therapy because the NS3 gene is considered one of the less variable genes in the HCV genome.

REFERENCES

1. Lohmann V, Körner F, Koch JO, Herian U, Thellmann L, Bartenschlager R (1999) Replication of subgenomic Hepatitis C virus RNAs in a hepatoma cell line. Science 285:110-113.

2. Pawlotsky JM (2004) Pathophysiology of Hepatitis C virus infection and related liver disease. Trends Microbiol 12:96-101.

3. Ramos de andrade junior D, Ramos de andrade D (2004) The influence on the human genome on chronic viral Hepatitis outcome. Rev Inst Med tro S Paulo 46:119-126.

4. Galossi A, Guarisco R, Bellis L, Puoti C (2007) Extrahepatic manifestations of chronic HCV infection. J Gastrointestin Liver Dis 16:65-73.

5. Houghton M, Abrignani S (2005) Prospects for a vaccine against the hepatitis C virus. Nature 436:961-965.

6. Kim JL, Morgenstern KA, Lin C, Fox T, Dwyer MD, Landro JA, Chambers SP, Markland W, Lepre CA, O'Malley ET, Harbeson SL, Rice CM, Murcko MA, Caron PR, Thomson JA (1996) Crystal structure of the Hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide. Cell 87:343-355.

7. Dubuisson J (2007) Hepatitis C virus proteins. World J Gastroenterol 13:2406-2415.

8. Guillou-Guillemette HL, Vallet S, Gaudy-Graffin C, Payan C, Pivert A, Goudeau A, Lunel-Fabiani F (2007) Genetic diversity of the Hepatitis C virus: Impact and issues in the antiviral therapy. World J Gastroenterol 13:2416-2426.

9. Chayama K, Tsubota A, Kobayashi M, Okamoto K, Hashimoto M, Miyano Y, Koike H, Kobayashi M, Koida I, Arase Y, Saitoh S, Suzuki Y, Murashima N, Ikeda K, Kumada H (1997) Pretreatment virus load and multiple amino acid substitutions in the interferon sensitivity-determining region predict the outcome of interferon treatment in patients with chronic genotype 1b hepatitis C virus infection. Hepatology 25:745-749.

10. Taylor DR, Puig M, Darnell MER, Mihalik K, Feinstone SM (2005) New antiviral pathway mediates Hepatitis C virus replicon interferon sensivity through ADAR1. J Virol 79:6291-6298.

11. Huang H, Sun F, Owen DM, Li W, Chen Y, Gale Jr. M, Ye J (2007) Hepatitis C virus production by human hepatocytes dependent on assenbly and secretion of very lowdensity lipoproteins. Proc Nat Acad Sci 14:5848-5853.

12. Wakita T, Pietscmann T, Kato T, Date T, Miyamoto M, Zhao Z, Murthy K, Habermann A, Kräusslich H, Mizokami M, Bartenschlager R, Liang TJ (2005) Production of infectious Hepatitis C virus in tissue culture from a cloned viral genome. Nature med 11:791-795.

13. Komoda Y, Hijikata M, Sato S, Asabe S, Kimura K, Shimotono K (1994) Substrate requirements of Hepatitis C virus serine proteinase for intermolecular polypeptide cleavage in Escherichia coli J Virol 68:7351-7357.

14. Chung V, Carroll AR, Gray NM, Parry NR, Thommes PA, Viner KC, D'Souza EA (2005) Development of cellbased assays for in vitro characterization of Hepatitis C virus NS3/4A protease inhibitors. Antimicrob Ag and Chem 49:1381-1390.

15. Nishikawa F, Kakiuchi N, Funaji K, Fukuda K, Sekiya S, Nishikawa S (2003) Inhibition of HCV NS3 protease by RNA aptamers in cells. Nucleic Acids Research 31:1935-1943.

16. Vallet S, Gouriou S, Nousbaum JB, Legrand-Quillien MC, Goudeau A, Picard B (2005) Genetic heterogeneity of the NS3 protease gene in Hepatitis C virus genotype 1 from untreated infected patients. J Med Virol 75:528-537.

17. Kou YH, Chang MF, Wang YM, Hung ZM, Chang SC (2007) Differential requirements of NS4A for internal NS3 cleavage and polyprotein processing of Hepatitis C virus J Virol 81: 7999-8008.